https://us.spindices.com/documents/indexnews/announcements/20200122-1077359/1077359_5payc.pdf?force_download=true
Piper Sandler Downgrades Nevro to Underweight, Lowers Price Target to $38
Piper Sandler analyst Adam Maeder downgrades Nevro (NYSE:NVRO) from Neutral to Underweight and lowers the price target from $42 to $38.